Figure 9. PFS among patients that received Lanreotide (red) or placebo (blue). This figure was retrieved and adapted from The New England journal of medicine, Caplin M. E., Pavel M., Cwikla J. B., et al., Lanreotide in metastatic enteropancreatic neuroendocrine tumors, 371 (3): 224-33 © 2014 (189).